The stock has a 36-month beta value of 0.35. Opinions on the stock are mixed, with 2 analysts rating it as a “buy”, 0 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for MNOV is 46.48M, and at present, short sellers hold a 0.35% of that float. On July 04, 2025, the average trading volume of MNOV was 12.90K shares.
MNOV stock’s latest price update
Medicinova Inc (NASDAQ: MNOV) has seen a decline in its stock price by -1.57% in relation to its previous close of $1.27. However, the company has experienced a -3.85% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-14 that LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital’s, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and private executives with institutional investors, high-net worth individuals, and corporate clients from various sectors including Healthcare & Life Sciences. Drs. Iwaki and Crean will be discussing MediciNova’s leading programs in neurologic and metabologic disorders. For more information about participation in the DBC Conference, visit https://dboralcapital.com/conference.
MNOV’s Market Performance
MNOV’s stock has fallen by -3.85% in the past week, with a monthly drop of -11.35% and a quarterly drop of -11.35%. The volatility ratio for the week is 4.26% while the volatility levels for the last 30 days are 3.76% for Medicinova Inc The simple moving average for the past 20 days is -5.98% for MNOV’s stock, with a -26.92% simple moving average for the past 200 days.
Analysts’ Opinion of MNOV
Many brokerage firms have already submitted their reports for MNOV stocks, with Maxim Group repeating the rating for MNOV by listing it as a “Buy”. The predicted price for MNOV in the upcoming period, according to Maxim Group is $15 based on the research report published on March 10, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MNOV reach a price target of $22. The rating they have provided for MNOV stocks is “Buy” according to the report published on March 25th, 2019.
MNOV Trading at -10.84% from the 50-Day Moving Average
After a stumble in the market that brought MNOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.98% of loss for the given period.
Volatility was left at 3.76%, however, over the last 30 days, the volatility rate increased by 4.26%, as shares sank -12.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.67% lower at present.
During the last 5 trading sessions, MNOV fell by -3.85%, which changed the moving average for the period of 200-days by -31.32% in comparison to the 20-day moving average, which settled at $1.3295. In addition, Medicinova Inc saw -13.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Medicinova Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for MNOV
The total capital return value is set at -0.25%. Equity return is now at value -20.33%, with -19.35% for asset returns.
Based on Medicinova Inc (MNOV), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -55.61.
Currently, EBITDA for the company is -11.02 million with net debt to EBITDA at 2.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.66.
Conclusion
To sum up, Medicinova Inc (MNOV) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
